Cell Therapies for Atrophic AMD

Related

• 

  One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO

  Mark R. Barakat, MD

  Updates from the Field

  2020

• 

  GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results

  Jeffrey S. Heier, MD

  Arshad M. Khanani, MD, MA, FASRS

  Updates from the Field

  2022

• 

  Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials

  Charles C Wykoff, MD, PhD, FASRS

  Updates from the Field

  2022